Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors

Oncology. 2014;86(2):122-6. doi: 10.1159/000357137. Epub 2014 Jan 28.

Abstract

Objective: Malignant peripheral nerve sheath tumors (MPNST) are a rare subtype of sarcoma, with a poor outcome. MPNST are regarded as being sporadic or associated with neurofibromatosis type 1 (NF1). Few comparative overall-survival (OS) data in these 2 subsets of MPNST patients exist. The aim of this retrospective study was to assess OS in sporadic and NF1-associated MPNST patients.

Methods: Fourteen consecutive patients with initial localized as well as initial metastatic MPNST were diagnosed and treated in our department. Patients with sporadic MPNST were assigned to group A and those with NF1-associated MPNST to group B.

Results: Eight versus 6 patients were allocated to groups A and B. Primary tumors were located on the extremities in all but 1 patient. Two patients in group A and 4 patients in group B experienced a relapse. Four patients died in each of the 2 groups. Median follow-up was 66.2 and 57.2 months in group A and group B, respectively. Median OS in group A was 46.9 months versus 12.7 months in group B.

Conclusions: In this small, single-center study, sporadic-MPNST patients had a longer median OS than those with NF1-associated MPNST.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nerve Sheath Neoplasms / drug therapy
  • Nerve Sheath Neoplasms / mortality*
  • Nerve Sheath Neoplasms / pathology
  • Neurofibromatosis 1 / drug therapy
  • Neurofibromatosis 1 / mortality*
  • Neurofibromatosis 1 / pathology
  • Retrospective Studies
  • Young Adult